Relationship of interleukin‐23 with matrix metalloproteinase‐9, pentraxin‐3, sleep quality and prostate size in benign prostatic hyperplasia

• Published in: Andrologia Vol. 54; no. 5; pp. e14387 - n/a
• Main Authors: Navaneethakannan, Mathiyazhagan, Nandeesha, Hanumanthappa, Sreenivasan, Sreerag K
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.06.2022
• Subjects: benign prostatic hyperplasia; C-Reactive Protein - metabolism; Cytokines; Enlargement; Genital diseases; Humans; Hyperplasia; Inflammation; Inflammation - complications; Interleukin-23; Interleukin-23 Subunit p19 - metabolism; Male; Matrix metalloproteinase; Matrix Metalloproteinase 9 - metabolism; Metalloproteinase; Multivariate analysis; Patients; Pentraxins; Prostate; Prostatic Hyperplasia - complications; Prostatic Neoplasms; Serum Amyloid P-Component - metabolism; Sleep; Sleep Quality; Tissue Inhibitor of Metalloproteinase-1; Tissue inhibitor of metalloproteinases; matrix metalloproteinase; inflammation; benign prostatic hyperplasia; sleep quality

Benign prostatic hyperplasia (BPH) is known to be associated with sleep disturbance and inflammation. The objective of the study was to assess the levels of serum MMP‐9 and its inhibitor (TIMP‐1), interleukin‐23 and pentraxin‐3 and their association with sleep quality index and prostate size in BPH...